Particle.news
Download on the App Store
5 ARTICLES
·
6d ago

GSK Acquires Promising Liver Disease Drug Efimosfermin in $2 Billion Deal

The acquisition strengthens GSK's hepatology pipeline with a potential best-in-class treatment targeting a 2029 market launch.

GSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. REUTERS/Dado Ruvic/Illustration/File Photo
Image
GSK boss Dame Emma Walmsley has set a target of generating group revenue of more than £40 billion by 2031
Image

Overview

  • GSK has agreed to pay $1.2 billion upfront, with up to $800 million in milestone payments, to acquire efimosfermin from Boston Pharmaceuticals.
  • Efimosfermin, a once-monthly injection for steatotic liver disease, is poised to enter late-stage clinical trials.
  • The drug aims to treat and prevent disease progression, complementing GSK's internal candidates and potentially saving the US healthcare system billions in costs.
  • Shares in GSK rose 1.8% following the announcement, reflecting investor confidence in the acquisition's strategic value.
  • This move aligns with GSK's broader strategy to expand its biopharma pipeline following its 2022 spin-off of Haleon and multiple bolt-on acquisitions.